Genetic Modifiers of Parkinson's Disease: A Case–Control Study
Our findings support the use of genetic screening to enrich candidate selection for neuroprotective trials and better define outcome measures based on genetics.
Authors
- Keaton Stagaman (ORCID: https://orcid.org/0000-0003-2815-4530)
- Joshua Gottesman (ORCID: https://orcid.org/0009-0004-8959-8754)
- Anna Guan
- Ruth B. Schneider (ORCID: https://orcid.org/0000-0001-8094-4041)
- Stella Aslibekyan
- Jingchunzi Shi (ORCID: https://orcid.org/0000-0002-9671-2568)
- Steven J. Micheletti (ORCID: https://orcid.org/0000-0002-3842-0946)
- Giulietta Riboldi (ORCID: https://orcid.org/0000-0003-0322-5718)
- Michael V. Holmes (ORCID: https://orcid.org/0000-0001-6617-0879)
- David A. Hinds (ORCID: https://orcid.org/0000-0002-4911-803X)
- Matthew J. Kmiecik (ORCID: https://orcid.org/0000-0001-5340-3872)
- Pierre Fontanillas (ORCID: https://orcid.org/0000-0002-8944-4454)
- Lucy Norcliffe‐Kaufmann (ORCID: https://orcid.org/0000-0003-0702-1333)
- Joyce Y. Tung
- Susana A. Tat
Institutions
- Michael J. Fox Foundation (US)
- University of Rochester Medical Center (US)
- 23andMe (United States) (US)
- New York University (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1002/acn3.70176
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Michael J. Fox Foundation for Parkinson's Research